Last reviewed · How we verify
HDG1901
HDG1901 is an investigational drug in Phase 3 development by Hangzhou Zhongmei Huadong Pharmaceutical, but its specific mechanism of action is not publicly disclosed.
At a glance
| Generic name | HDG1901 |
|---|---|
| Sponsor | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without access to detailed clinical trial data or published literature on HDG1901, the precise molecular target and mechanism cannot be reliably determined. The drug remains in Phase 3 development, suggesting it has shown promise in earlier trials, but mechanistic details are typically proprietary until regulatory approval or formal publication.
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects. (PHASE1)
- Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |